Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

Arthritis and Rheumatism
Samy SuissaPierre Ernst

Abstract

Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently. To assess this risk, we conducted a population-based epidemiologic study. A cohort of 62,734 patients with RA to whom a DMARD had been dispensed between September 1, 1998 and December 31, 2003 was formed using the PharMetrics claims database. A nested case-control design was used, in which each case of serious ILD requiring hospitalization was matched to 100 controls according to age (calendar time) and equal or greater duration of followup, to estimate adjusted rate ratios (RRs) of serious ILD associated with DMARD use. There were 74 cases of serious ILD, which corresponds to a rate of 8.1 per 10,000 patients per year. The risk of ILD was increased with the use of leflunomide (adjusted RR 1.9 [95% confidence interval (95% CI) 1.1-3.6]). Among subjects with no previous methotrexate use and no history of ILD, the risk associated with leflunomide treatment was not elevated (RR 1.2 [95% CI 0.4-3.1]), but it was elevated among the remaining subjects (RR 2.6 [95% CI 1.2-5.6]). Patients with a history of ILD were twice as likely to hav...Continue Reading

References

Aug 19, 2003·Rheumatology·V Saravanan, C A Kelly
Feb 18, 2004·Lancet·Justin McCurry

❮ Previous
Next ❯

Citations

Jun 4, 2011·Journal of Neurology·Dorothea Buck, Bernhard Hemmer
Apr 9, 2008·Pathology Oncology Research : POR·Ildiko Fanny HorvathMargit Zeher
Apr 24, 2013·Drugs·Rehiana AliPaolo Antonio Muraro
Nov 5, 2013·Revue de pneumologie clinique·L Essaadouni, L Benjilali
Jan 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Wu-xing ZhangXue-wei Zhao
Mar 27, 2009·Rheumatology·Batsi ChikuraJulie K Dawson
Mar 27, 2009·Rheumatology·Tetsuji SawadaUNKNOWN Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology
Jun 25, 2009·Rheumatology·Clive Kelly
Jun 11, 2011·Pulmonary Medicine·Mark J Hamblin, Maureen R Horton
Sep 18, 2007·American Journal of Respiratory Cell and Molecular Biology·R Stokes Peebles, Martin L Moore
Oct 10, 2013·Practical Neurology·Claire M Rice
Sep 30, 2010·Immunotherapy·Sven Teschner, Volker Burst
Dec 4, 2009·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·S P Y WongW L Ng
Feb 9, 2012·Journal of Medical Economics·Qayyim SaidStephen C Mathai
Feb 18, 2015·Expert Opinion on Drug Safety·Athina PapadopoulouTill Sprenger
May 15, 2013·Expert Opinion on Drug Safety·Helen I KeenSusan E Tett
Jul 28, 2007·Scandinavian Journal of Rheumatology·F WolfeK Michaud
Mar 12, 2008·Cutaneous and Ocular Toxicology·Xingdong JianXingfu Li
Oct 30, 2012·Immunology and Allergy Clinics of North America·Keith C Meyer, Jennifer Bierach
Jun 19, 2012·The Medical Clinics of North America·Anne V Miller, Sriya K M Ranatunga
Mar 1, 2012·Clinics in Chest Medicine·Danielle Antin-OzerkisRichard A Matthay
Oct 4, 2011·Journal of the American Academy of Dermatology·Alan S Boyd
Mar 4, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Malte C Claussen, Thomas Korn
Feb 9, 2011·Pulmonary Pharmacology & Therapeutics·Ryuji KoikeMasayoshi Harigai
Jan 5, 2011·La Presse médicale·Anat AmitalYochai Adir
Aug 10, 2010·Clinics in Chest Medicine·Danielle Antin-OzerkisRichard A Matthay
Aug 10, 2010·Clinics in Chest Medicine·Keith C MeyerRobert Baughman
Nov 17, 2009·Seminars in Arthritis and Rheumatism·Atul A Khasnis, Leonard H Calabrese
Oct 7, 2008·European Journal of Pharmacology·Masashi DeguchiAkinori Arimura
Jan 10, 2012·Annals of the New York Academy of Sciences·Shiv SaidhaPeter A Calabresi
Jun 25, 2015·Pharmacoepidemiology and Drug Safety·Anaïs LacasseManon Choinière
Apr 4, 2015·Rheumatic Diseases Clinics of North America·Zulma X Yunt, Joshua J Solomon
Dec 25, 2015·American Journal of Respiratory Cell and Molecular Biology·Chao HeA Brent Carter
Dec 2, 2015·Therapeutic Advances in Musculoskeletal Disease·Kundan Iqbal, Clive Kelly

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.